Therapeutic plasma exchange in thrombotic thrombocytopenic purpura - 04/12/19
Summary |
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease related to the formation of microvascular thrombosis and subsequent organ failure. The disease is accompanied with microangiopathic haemolytic anaemia, consumptive thrombocytopenia and lies on a severe deficiency in ADAMTS13, the von Willebrand factor-cleaving protease. In the acquired, immune-mediated form, this deficiency is due to the production of autoantibodies directed against the enzyme. Therapeutic plasma exchange has been used empirically for decades and still represents the cornerstone of TTP treatment. However, a better understanding of pathophysiological mechanisms underlying the disease has led these last years to the development of highly effective targeted therapies that might in the future restraint the use of therapeutic plasma exchange.
Le texte complet de cet article est disponible en PDF.Plan
Vol 48 - N° 11P2
P. 319-327 - novembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.